top of page
The Professional Network for Healthcare Experts
Eli Lilly partners with Hims & Hers to expand access to Zepbound and Foundayo obesity medicines
Lilly's commercial partnership with Hims & Hers brings two FDA-approved obesity treatments into an integrated telehealth prescribing and delivery pathway, with published self-pay starting prices from $149 per month.
nuaxia
2 days ago2 min read
Corxel agrees $377 million SPAC combination with Amanat to fund oral obesity drug development
Corxel Pharmaceuticals US has agreed to merge with Amanat Acquisition Corp in a SPAC transaction expected to provide approximately $377 million in gross proceeds for its oral obesity drug pipeline.
nuaxia
Oct 282 min read
bottom of page